VINPOCETINE

Active material: Vinpocetine
When ATH: N06BX18
CCF: Preparation, improves blood circulation and metabolism of the brain
ICD-10 codes (testimony): F01, F07, G45, G45.0, G93.4, H34, H35.0, H35.3, H40.5, H81, H81.0, H93.0, I61, I63, I67.2, I67.4, I69, N95.1, N95.3
When CSF: 02.15
Manufacturer: ALSI Pharma Company Inc. (Russia)

Pharmaceutical form, composition and packaging

Pills white or white with a yellowish tint, ploskotsilindricheskoy form, a facet and Valium.

Excipients: lactose, colloidal silicon dioxide (aэrosyl), potato starch, talc, magnesium stearate.

10 PC. – packings Valium planimetric (1) – packs cardboard.
10 PC. – packings Valium planimetric (2) – packs cardboard.
10 PC. – packings Valium planimetric (3) – packs cardboard.
10 PC. – packings Valium planimetric (4) – packs cardboard.
10 PC. – packings Valium planimetric (5) – packs cardboard.

Pharmacological action

Vazodilatirtee tool. It improves metabolism of the brain, increasing the consumption of glucose and oxygen to the tissues of the brain. It increases resistance of neurons to hypoxia; facilitates the transport of glucose to the brain, through the blood-brain barrier; translates the process of dissolution of the glucose to energy more economical, aerobic path; Are selectively blokiruet ²⁺ – dependent phosphodiesterase; increases the content of adenozinmonofosfata (AMF), cyclic Guanosine monophosphate (cGMP), ATP, noradrenaline, serotonin and ATP/AMP ratios in the tissues of the brain; It has an antioxidant effect.

Reduces the aggregation of platelets and increased blood viscosity; It increases the ability of red blood cells deforming and blocks adenosine utilization by erythrocytes; contributes to enhanced oxygen cell.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without significant changes in the systemic circulation figures. Has no effect “steal” and increases the blood supply, primarily, Ischemic areas of the brain.

Pharmacokinetics

Rapidly absorbed. T_max – 1 no. Absorption occurs, mainly, in the proximal gastrointestinal divisions. When passing through the wall of kišečnikane metabolizmu.

The maximum concentration in tissues through 2-4 hours after receiving inside. Contact proteins – 66%, the absolute bioavailability of ingestion – 7%, increases in use of the drug after a meal. Clearance 66,7 l /. exceeds the plasma volume of liver (50 l /), reflecting on vnepečënočnom metabolism.

Repeated receptions kinetics is linear in nature. T_1/2 in humans, 4.83 ± 1.29 h. Report the news and through the intestines in the ratio 3:2. It penetrates through the placental barrier.

Testimony

-neurological and psychiatric symptoms in various forms of insufficiency of cerebral blood flow (incl. restorative stage ischemic or gemmoragičeskogo stroke, the effects of a stroke; tranzitornaya ishemicheskaya attack; sosudistaya dementia; vertebrobasilar insufficiency; cerebral atherosclerosis; posttraumatic and hypertensive encephalopathy);

-chronic vascular diseases of choroid and retina (as a result of arteriosclerosis, angiospazma, thrombosis); macular degenerative changes, caused by atherosclerosis or angiospazmom; secondary glaucoma (due to the obstruction of vessels);

-age-related vascular or toxic (medication) hearing loss, Meniere's disease, idiopathic tinnitus, dizziness labyrinth origin;

— vazovegetativnye manifestations of menopausal syndrome.

Dosage regimen

Inside of 5 mg (1 tab.) after meal. The drug is applied 3 times / day. The initial daily dose is 15 mg. The maximum daily dose 30 mg. The duration of treatment to 3 Months. Repeated courses are possible 2-3 per year.

At kidney or liver disease the drug is prescribed in the usual dose.

Before canceling, dosage should be reduced gradually.

Side effect

Cardio-vascular system: ECG changes (ST depression, QT prolongation), tachycardia, arrythmia, labile blood pressure, feeling the tides.

CNS: sleep disorders (insomnia, hypersomnia), dizziness, headache, generalized weakness, increased perspiration.

On the part of the digestive system: dry mouth, nausea, heartburn.

Allergic skin reactions.

Contraindications

- The acute phase of hemorrhagic stroke, coronary artery disease, pronounced arrhythmia.

-hypersensitivity to any component of the drug.

- Pregnancy (may placentar bleeding and spontaneous abortion, probably, as a result of increased placental blood supply).

- Lactation (in applying the drug must stop breastfeeding).

-children up to 18 years (the lack of data).

Tablets contain lactose, Therefore the drug should not be taken by patients with rare hereditary diseases, such as Galactose intolerance, lactase deficiency or glucose-galaktoznaâ malabsorption.

Pregnancy and lactation

The drug is contraindicated in pregnancy and lactation.

Cautions

The existence of the syndrome of prolonged QT interval and medications, causing QT prolongation, It requires periodic monitoring of ECG.

Effects on ability to drive vehicles and management mechanisms

Data on the impact of vinpocetina on the ability to driving and work, requiring psychomotor speed reactions no.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, simptomaticheskaya therapy.

Drug Interactions

There is no interaction with β-adrenergic (xloranolol, pindolol), klopamydom, glibenclamide, digoksinom, acenokumarolom and hydrochlorothiazide, imipramine.

The simultaneous use of vinpocetina and metildopa sometimes caused some increased gipotenzivnogo effect, Therefore, when such treatment requires regular monitoring of blood pressure.

Increases the risk of bleeding complications in geparinoterapii.

Despite the lack of data, supporting interoperability, are advised to be cautious while appointing Central drugs, protivoaritmičeskogo and antikoagulântnogo actions.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

List B. In dry the dark spot, at a temperature not higher 25 ° C.

Keep out of the reach of children.

Shelf life 5 years. Do not use beyond the expiration date, on the package.